Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...
Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Medpage Today on MSN4d
Managing Primary Biliary Cholangitis Progression and SymptomsOnce clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello everyone, and welcome to the Mirum Pharmaceuticals’ Third ...
Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback